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Abstract
Breast cancers with a basal-like gene signature are primarily triple-negative, frequently metastatic, and carry a poor
prognosis. Basal-like breast cancers are enriched for markers of breast cancer stem cells as well as markers of epithelial-
mesenchymal transition (EMT). While EMT is generally thought to be important in the process of metastasis, in vivo evidence
of EMT in human disease remains rare. Here we report a novel model of human triple-negative breast cancer, the DKAT cell
line, which was isolated from an aggressive, treatment-resistant triple-negative breast cancer that demonstrated
morphological and biochemical evidence suggestive of phenotypic plasticity in the patient. The DKAT cell line displays a
basal-like phenotype in vitro when cultured in serum-free media, and undergoes phenotypic changes consistent with EMT/
MET in response to serum-containing media, a unique property among the breast cancer cell lines we tested. This EMT is
marked by increased expression of the transcription factor Zeb1, and Zeb1 is required for the enhanced migratory ability of
DKAT cells in the mesenchymal state. DKAT cells also express progenitor-cell markers, and single DKAT cells are able to
generate tumorspheres containing both epithelial and mesenchymal cell types. In vivo, as few as ten DKAT cells are capable
of forming xenograft tumors which display a range of epithelial and mesenchymal phenotypes. The DKAT model provides a
novel model to study the molecular mechanisms regulating phenotypic plasticity and the aggressive biology of triple-
negative breast cancers.
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Introduction
Breast cancer is a heterogeneous disease that exhibits a wide
range of clinical behaviors, prognoses, and histologies. Gene
expression profiling of patient samples initially identified five
breast cancer subgroups (luminal A and B, Her2 amplified,
normal-like, and basal-like subtypes), each with a distinct
molecular signature [1–3]. Tumors with a basal-like gene
signature are primarily triple-negative (ER2/PR2/Her2wt),
frequently occur in young African American women and BRCA1
mutation carriers, and carry the worst prognosis [2–5]. While
some triple-negative breast cancers respond to treatment, a subset
are highly invasive and metastatic and do not respond to
chemotherapy or radiation [6]. Recent studies have shown that
triple-negative breast cancers are enriched for markers of
epithelial-mesenchymal transition (EMT), a process generally
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thought to be important in the metastatic cascade [7,8]. Other
recent work has demonstrated a link between EMT and stem cell-
like characteristics in mammary epithelial cells, and that an EMT
and stem cell-like gene expression signature is found in residual
breast cancer cells following chemotherapy [9,10]. Collectively,
these studies suggest that epithelial-mesenchymal plasticity may be
important for the highly aggressive subset of triple-negative breast
cancers.
Epithelial-mesenchymal transition is a part of normal physio-
logical processes, including embryogenesis and wound healing, in
which cells of epithelial origin lose epithelial characteristics and
polarity and acquire a mesenchymal phenotype associated with
increased migratory behavior [11–14]. Activation of an EMT-like
program in cancer cells in vitro similarly results in increased cell
migration and invasion as well as increased resistance to apoptosis
[7,11]. At the molecular level, EMT is characterized by 1) loss of
expression of membranous E-cadherin, claudins, and occludins, 2)
increased expression of mesenchymal markers including vimentin
and smooth muscle actin, 3) acquisition of a spindle-like
morphology, and 4) cytoskeleton reorganization [12,14]. The
reverse process, mesenchymal-epithelial transition (MET), is
characterized by a loss of expression of mesenchymal markers
and restoration of epithelial markers and morphology [13,15].
The similarities between the developmental EMT events and
the process of tumor cell dissemination, in which cells lose contact
with the primary tumor and invade into the normal host tissue and
blood vessels, has lead to the hypothesis that EMT is an important
part of the metastatic cascade (10–13). However, there is difficulty
in identifying EMT in human breast cancer because the full
sequence of events that have come to define EMT in vitro are not
commonly observed in vivo (29), and metastases commonly have an
epithelial phenotype similar to the primary tumor. In order to
reconcile the observations of breast cancer pathologists with in vitro
studies of breast cancer cell lines, it has been proposed that EMT
in the human tumor setting may be transient and reversible, and
that this phenotypic plasticity may be a key determinant of
metastatic potential [7,15,16].
The study of plasticity in human breast cancer is currently
limited by a lack of appropriate models that can reversibly
transition from the epithelial to mesenchymal state. Here we
report the isolation and characterization of the DKAT cell line, a
novel model of triple-negative breast cancer that was isolated from
a rapidly progressing, treatment-resistant, metastatic human breast
cancer. In vitro, DKAT cells are able to undergo phenotypic
changes consistent with EMT/MET in response to altered culture
conditions and express markers of breast cancer stem cells,
suggesting inherent phenotypic plasticity. Similar to the human
tumor from which the cell line was isolated, in xenograft
experiments DKAT cells form heterogeneous tumors with regions
of both epithelial and mesenchymal characteristics. The DKAT
cell line provides a new model to investigate the molecular
mechanisms of phenotypic plasticity in aggressive triple-negative
breast cancers.
Results
Evidence Suggestive of Epithelial-mesenchymal Plasticity
in a Human Triple-negative Breast Cancer
The DKAT cell line was derived from the malignant pleural
effusion of a 35-year-old Caucasian woman with no family history
of breast or ovarian cancer. The patient initially presented with a
4 cm ER/PR(2/2), HER2/Neu-wt, CK5(+), EGFR(+), lymph
node-negative breast cancer (T2N0M0). At the sixth cycle of
cyclophosphamide, methotrexate, and 5-fluorouracil, seven
months from the initial diagnosis, recurrent cancer was detected
within the chest wall radiation field. At ten months from initial
diagnosis, metastases to the lung, pleura, liver, and bone were
observed. At eleven months, the patient developed pancytopenia;
a bone marrow biopsy revealed multiple foci of tumor cells within
the bone marrow. At this time the tumor was not responsive to
taxotere and navelbine. At twelve months from initial diagnosis the
patient died from pancytopenia and rapid disease progression.
The primary breast cancer surgical specimen demonstrated a
range of phenotypes. Six widely separated microfocal neoplastic
lesions were identified that exhibited varying morphological and
immunohistochemical features (summarized in Table 1). Primary
Tumor Foci #1-5 stained strongly for the epithelial marker E-
cadherin and displayed only scattered weak staining for CK8/18,
CK5, and the mesenchymal marker vimentin (Figure 1, top row).
In contrast, Primary Tumor Focus #6 was strongly positive for
vimentin and CK5 as well as CK8/18 and E-cadherin (Figure 1,
second row). Similar to Primary Tumor Focus #6, the chest wall
recurrence contained solid sheets of malignant cells that were
positive for vimentin, CK5, and CK8/18, but E-cadherin staining
was notably less intense (Figure 1, third row). The staining pattern
of the malignant cells found in the bone marrow, however, was
similar to the epithelial staining pattern observed in Primary
Tumor Foci #1-5 with cells staining strongly for CK5, CK8/18
and membranous E-cadherin, but not vimentin (Figure 1, bottom
row). These observations show that the original primary tumor
contained both epithelial and mesenchymal regions, the chest wall
recurrence displayed increased expression of mesenchymal mark-
ers but still retained epithelial markers, suggesting an intermediate
phenotypic state, while the metastatic lesions in the bone strongly
expressed epithelial markers. A complete list of markers expressed
in the primary tumor, chest wall recurrence, and bone marrow
metastasis is provided in Table 1. While these observations could
be the result of clonal heterogeneity within the tumor, another
possible explanation is they represent areas of progression through
a transient EMT/MET. Therefore, we tested the cell line derived
from this patient for phenotypic plasticity in culture.
In vitro Characteristics of DKAT Cell Line Reflect the
Primary Tumor
Cells isolated from the patient’s malignant pleural effusion
rapidly adapted to tissue culture conditions. Forty-eight hours after
isolation (passage 1) DKAT cells began proliferating in culture
with a doubling time of approximately 24 hours (data not shown).
The DKAT cell line has been maintained continuously in culture
for .70 passages. Twenty-five metaphase DKAT cells (passage 3)
were subjected to spectral karyotyping (SKY) analysis, and an
additional 9 cells were G-banded and karyotyped (Figure 2). The
modal chromosome number was 56. In addition to 29 cells with
the hyperdiploid chromosome number, 3 cells had hypopentaploid
chromosome number (104–109 chromosomes) and 2 cells had
either 117 or 127 chromosomes. Among the predominant
hyperdiploid cells, two clones, a stemline and a sideline 1, were
identified. The only difference between the stemline and sideline 1
is the presence of one double minute (dmin) in a sideline. Because
of its small size, the origin of this double minute could not be
identified with confidence. Sideline 2 is near-tetraploid and
represents a doubling of the stemline, with some random
chromosome losses and a few non-clonal aberrations in the cells,
and sideline 3 is a composite karyotype of 2 cells with the highest
chromosome numbers.
Aggressive triple-negative breast cancers frequently contain
mutations in the TP53 and PIK3CA genes [2,17,18]. Sequencing of
exons 5–9 of the TP53 gene in DKAT cells identified a single point
EMT/MET in Triple-Negative Breast Cancer
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mutation in exon 8 at codon 273 (CGT . CAT). This is a
missense mutation previously described in the MDA-MB-468
breast cancer cell line, and reported to be deleterious to p53
function [19,20]. In breast tumors, PIK3CA mutations have been
found to frequently occur in exons 9 and 20 [21]. Sequencing of
PIK3CA exons 9 and 20 from DKAT genomic DNA revealed no
mutations within the coding region of these two exons.
A variety of techniques were used to test DKAT cells for
baseline expression of proteins associated with triple-negative
breast cancers and an aggressive phenotype including markers of
EMT, progenitor-like cell markers, and markers of PI3K/AKT
pathway activation. A summary of baseline DKAT expression
data is provided in Table 2. Immunohistochemical analysis
showed that DKAT cells did not stain for ER/PR but stained
positively for EGFR, and fluorescence in situ hybridization
demonstrated diploid copy number of HER2, consistent with the
triple-negative primary human tumor (data not shown). Immuno-
fluorescence and western blotting showed that DKAT cells express
Figure 1. Human breast cancer specimen displays morphological and biochemical evidence suggestive of EMT and MET. Images of
the patient’s primary tumor focus #3 (top row), focus #6 (second row), chest wall recurrence (third row), and bone marrow biopsy (bottom row)
showing H&E staining and immunohistochemistry for CK5, CK8/18, vimentin, and E-cadherin.
doi:10.1371/journal.pone.0045684.g001
Table 1. Characterization of human primary tumor, chest wall recurrence and bone marrow metastasis.
Marker Primary Foci #1-5 Primary Foci #6 Chest Wall Recurrence Bone Marrow Metastasis
ER (2) (2) nt nt
PR (2) (2) nt nt
HER2/neu Not amplified Not amplified nt nt
CK5 (+) (++) (++) (+++)
CK14 (+) (+) (+) (+)
CK8/18 (+) (++) (+) (+++)
E-cadherin
membrane (++) (+) (+) (+++)
cytoplasmic (++) (++) (+) (++)
Vimentin (+) (+++) (+++) (+)
Qualitative evaluation based on in situ hybridization for Her2, and based on immunohistochemistry for all other markers.
doi:10.1371/journal.pone.0045684.t001
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other markers consistent with basal mammary epithelial cells,
including CK5 and CK17, p63, and E-cadherin, which was found
localized to the membrane and throughout the cytoplasm
(Figure 3A). DKAT cells also express the luminal epithelial cell
marker CK18, although all other cell lines tested also expressed
CK18 including the mesenchymal MDA-MB-231 line [22,23].
Western blot analyses demonstrated that DKAT cells express a
high level of Akt phosphorylated at Serine 473, a common feature
Figure 2. DKAT cell line karyotype. A representative mitotic DKAT cell from sideline 1 is shown. A. Metaphase cell with chromosomes shown in
SKY display colors. B. Inverted and contrast-enhanced DAPI image of the same metaphase cell. C. The same metaphase cell with chromosomes
shown in spectra-based classification colors. D. Spectral karyotype of the same metaphase cell shown in SKY display colors.
doi:10.1371/journal.pone.0045684.g002
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of triple-negative breast cancers (Figure 3B) [24]. While we did not
observe mutations in PIK3CA exons 9 or 20, Akt phosporylation
at Ser 473 may be explained by the relatively low levels of PTEN
in the DKAT cell line (Figure 3B). FACS analysis of the cell
surface markers CD44 and CD24 revealed that the DKAT cell
line has a high percentage of cells of the CD44+/CD242/low
phenotype reported to be enriched for tumorigenic and stem-like
cell activity [25,26] and more recently associated with cells that
have undergone EMT [10,27] (Figure 3C). Taken together, these
observations demonstrate that DKAT cells exhibit baseline
expression of basal and luminal epithelial markers, phosphoryla-
tion of AKT-Serine 473, and express progenitor-like cell markers.
In order to assess the relationship of DKAT cells to published
breast cancer subtypes, we performed unsupervised hierarchical
clustering of DKAT transcript expression. Comparing our
experimental data with a previously published analysis of breast
cancer cell lines [28], we found that the DKAT gene expression
profile clustered with a number of basal-type cell lines (Figure 3D,
Figure S1). DKAT cells cluster most closely with SUM-149 cells,
but also with 184B5, MCF-10A, and HMEC cells. Parallel analysis
of control MDA-MB-231 and HMEC transcripts showed a high
correlation to previously published microarray data (r = 0.70 and
r = 0.84, respectively), validating the effectiveness of combining
these two data sets.
Evidence for Reversible EMT/MET in vitro
DKAT cells were derived from a breast cancer that exhibited a
diverse range of phenotypes, but it is unclear whether this
phenotypic diversity was the result of 1) outgrowth or evolution of
specialized subpopulations of cells within the primary tumor or 2)
phenotypic plasticity inherent within the tumor cells. We tested
DKAT cells for evidence of phenotypic plasticity by altering
culture conditions and testing for in vitro EMT/MET.
Western blot analysis demonstrated that at baseline, DKAT
cells grown in Mammary Epithelial Growth Media (MEGM)
expressed E-cadherin and a low level of vimentin (Figure 3B).
Immunofluorescence studies showed that DKAT cells cultured in
MEGM stained positive for the epithelial markers CK5, CK18,
and E-cadherin, which was found both at the membrane and
throughout the cytoplasm. Staining for the mesenchymal marker
vimentin was weak and scattered (Figure 4A).
To induce in vitro EMT, DKAT cells were switched from serum-
free MEGM to Stromal Cell Growth Media (SCGM) containing
insulin, bFGF, and 5% FBS. In contrast to their epithelial
phenotype when grown in MEGM, DKAT cells grown in SCGM
for 14 days were predominately vimentin-positive and E-cadherin-
negative, though a small percentage of cells retained an epithelial
staining pattern (Figure 4A). Additionally, we observed a
significant decrease in epithelial markers CK5 and CK18,
consistent with a shift from expression of cytokeratin intermediate
filaments to vimentin [29] (Figure 4A). While CK5 was uniformly
downregulated, CK18 was still expressed at low levels in some of
the cells. Strikingly, within 2 hours of being cultured in SCGM,
DKAT cells underwent a morphological change to a more spindle-
shaped and less cobblestone appearance (Figure 4B).
To assess expression of E-cadherin and vimentin at various time
points after the switch to SCGM, DKAT cells were cultured in
SCGM and protein lysate was collected 1 hour, 24 hours, or 14
days later. DKAT cells cultured in SCGM demonstrated a 100-
fold increase in vimentin expression as early as 1 h, and expression
of E-cadherin was strongly decreased by day 14 (Figure 4C). While
we did not observe a rapid downregulation of E-cadherin protein
by western blot following SCGM treatment, immunofluorescence
demonstrated that within 2 hours of SCGM treatment, E-cadherin
was predominately localized in the cytoplasm and away from the
membrane (Figure 4B).
We next tested whether DKAT cells grown in SCGM
demonstrated increased migration using a scratch/wound healing
assay. DKAT cells grown in SCGM for 14 days migrated to fill the
area of the scratch more quickly than DKAT cells in MEGM, with
almost 100% closure by DKAT-SCGM cells at 12 hr versus 60%
closure for DKAT-MEGM cells (Figure 4D). This increased
migratory behavior further supports the mesenchymal phenotype
of DKAT cells grown in SCGM.
It is possible that rather than inducing EMT, long-term culture
in SCGM results in the selection of cells already in the
mesenchymal state. To further investigate this possibility, we
sub-cultured clonal populations derived from single DKAT cells in
MEGM. We observed that one such clonal population with low
vimentin and high E-cadherin levels in MEGM underwent the
same vimentin upregulation and E-cadherin downregulation when
cultured in SCGM, with similar kinetics as the bulk population of
DKAT cells (Figure 4E).
To test for the ability of DKAT cells to undergo in vitro MET,
we took DKAT cells that had been cultured in SCGM for 10
passages and exhibited a mesenchymal phenotype, and switched
them back to growth in MEGM media. Five passages after being
returned to MEGM, DKAT cells demonstrated a significant
decrease in vimentin expression and increase in E-cadherin
(Figure 4F), consistent with a reversion to the original epithelial
phenotype. Western blotting also showed dramatically increased
expression of the mesenchymal marker N-cadherin and decreased
levels of epithelial markers CK17 and claudin-1 after 14 days in
SCGM. Five passages after being returned to MEGM, N-cadherin
expression was significantly decreased and CK17 and claudin-1
returned to their original expression levels (Figure 4F).
We also tested a clonal population derived from a single
DKAT-SCGM cell with a mesenchymal phenotype for the ability
to undergo in vitro MET. Following 14 days in MEGM,
immunofluorescence for E-cadherin and vimentin showed that
this clonal cell line contained cells with two predominantly two
different phenotypes (Figure 4G). One population was morpho-
logically cobblestone in appearance and stained positive for
membranous E-cadherin and negative for vimentin. A second
population displayed a more spindle-shaped morphology and was
E-cadherin-negative and vimentin-positive. Taken together, these
observations provide evidence that in response to altered culture
conditions, DKAT cells undergo phenotypic and morphological
changes consistent with EMT and MET.
In order to determine if the properties of the DKAT cell line are
unique or whether growing any breast cancer line in MEGM or
SCGM would result in similar phenotypic shifts, we cultured a
variety of breast cell lines in MEGM or SCGM. MDA-MB-231
breast cancer cells are categorized as Basal B or mesenchymal
according to gene expression profiling [28,30,31] and are
frequently used to study breast cancer metastasis. These cells are
typically cultured in medium containing 5–10% FBS, therefore we
cultured this cell line in MEGM and looked for evidence of MET.
After 14 days in MEGM, western blotting showed no change in
the level of E-cadherin or vimentin protein expression, indicating
MET had not occurred (Figure 4H).
Conversely, MCF-7, SUM-149, and SUM-190 breast cancer
cells are normally grown in media containing 5–10% FBS and
express epithelial markers. After culturing these three cell lines in
SCGM for 14 days, we saw no evidence of EMT (Figure 4H).
Furthermore, culturing these two cell lines in MEGM did not have
an effect on the expression of E-cadherin or vimentin. Finally, we
also tested the effect of growing hTERT-immortalized human
EMT/MET in Triple-Negative Breast Cancer
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Figure 3. DKAT cells express markers of basal epithelial cells. A. Immunofluorescence for CK5, CK17, p63 and CK18 in DKAT, immortalized
HMEC, MCF-7, and MDA-MB-231 cells. B. Western blotting of total cell lysates from HMEC, MCF-7, MDA-MB-231, and DKAT cells grown in MEGM. C.
FACS analysis of DKAT-MEGM, MCF-7 and MDA-MB-231 cells stained for CD44 and CD24. D. Results from DKAT, MDA-MB-231, and HMEC Affymetrix
EMT/MET in Triple-Negative Breast Cancer
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mammary epithelial cells (HMECs) in SCGM for 14 days. While
culturing these cells in SCGM did result in decreased E-cadherin
and a small increase in vimentin (Figure 4H), the non-transformed
cells did not proliferate in the presence of serum and arrested
during the 14 day time course [32] (data not shown). These
experiments demonstrate that the DKAT cell line is unique among
the tested breast cancer models for its ability to reversibly
transition between an epithelial or mesenchymal phenotype based
on the culture media in which the cells are grown.
mRNA expression was compared in DKAT cells grown for 14
days in MEGM versus SCGM. As expected, DKAT cells grown in
SCGM media demonstrated a significant decrease in epithelial-
specific gene expression, including genes that regulate adhesion
and cell-cell junctions. A significant increase in genes associated
with a mesenchymal phenotype and cellular transformation was
also observed. A partial list of differentially expressed genes is
presented in Table 3. Of note, there was a decrease in expression
of KRT6C (CK6; 131.8-fold), KRT5 (CK5; 37.0-fold), TP63 (p63;
26.2-fold), KRT17 (CK17; 7.8-fold), KRT14 (CK14; 3.0-fold), and
CLDN1 (claudin-1; 2.9-fold) and an increase in TGFA (TGF-alpha;
2.3-fold), TGFBI (TGF-beta-induced; 2.6-fold), LOX (lysyl oxidase;
2.9-fold), ALDH1A3 (ALDH-1a3; 3.6-fold), CDH2 (N-cadherin;
5.6-fold), and FGF2 (FGF2; 6.0-fold). As shown in Figure 4F,
western blotting for claudin-1, cytokeratin 17, and N-cadherin
from protein lyastes of DKAT cells that had undergone EMT/
MET as described above confirmed the results of the microarray
data.
Zeb1 Regulates DKAT Cell Plasticity
A large number of transcription factors are implicated in the
process of EMT, including members of the Snail, bHLH, and Zeb
families, all of which have been reported to be capable of
repressing E-cadherin and inducing EMT in various cell types
[33]. In order to further investigate the mechanisms underlying
epithelial plasticity in the DKAT cell line, we looked at the
expression of three of these transcription factors in the DKAT
model. Western blotting showed no noticeable difference in
expression of Snail1 and Twist protein between DKAT cells
grown in MEBM versus SCBM. However, Zeb1 was noticeably
increased in DKAT-SCGM cells compared to DKAT-MEGM
cells (Figure 5A). Zeb1 is a zinc-finger transcription factor that
binds directly to the E-cadherin promoter and represses its
transcription [34]. To determine if over-expression of Zeb1 is
sufficient to induce phenotypic changes consistent with EMT, we
constitutively expressed Zeb1 in epithelial DKAT-MEGM cells.
Constitutive over-expression of Zeb1 resulted in a shift to a
mesenchymal phenotype, evidenced by decreased expression of E-
Cadherin and Claudin-1 and increased vimentin (Figure 5B).
Notably, stable knockdown of Zeb1 using two different lentiviral
shRNA sequences prevented the increase in migration when
DKAT cells were switched from MEGM to SCGM (Figure 5C).
Together, these data indicate that Zeb1 is important in both the
induction of EMT in the DKAT model and the increased
migratory ability of the mesenchymal DKAT cells.
DKAT Cells are Highly Tumorigenic and Exhibit in vivo
Plasticity
To test the tumorigenic potential of the DKAT cell line, 104,
103, 102, or 10 cells grown in MEGM were injected into the
mammary fat pad of immunocompromised mice. Palpable tumors
were present within 2–4 weeks and most animals were sacrificed
by 13 weeks post-injection with tumors of 15 mm diameter. We
observed that 8/8 mice developed tumors at doses of 104, 103 and
102 cells/injection. Importantly, 2/8 mice formed tumors when
only 10 cells were injected, indicating the significant tumorigenic-
ity of the DKAT cell line.
Similar to the human cancer of origin, DKAT xenograft tumors
exhibited a range of morphological patterns and immunohisto-
chemical staining. Three recurring morphological patterns were
observed in DKAT xenografts transplanted without Matrigel.
Pattern I: Infiltrating growth without dense fibrous matrix
(Figure 6Ai). DKAT cells formed cords and columns of neoplastic
cells that infiltrated the surrounding fat and stained positive for
CK5. Pattern II: Infiltrating growth with dense fibrous matrix
(Figure 6Aii). DKAT cells formed nests and cords of cells
surrounded by a dense connective tissue. Notably, DKAT cells
were observed inside the ducts of the host mammary gland
demonstrating the ability of DKAT cells to invade through the
HG-U133 2+ arrays were analyzed by unsupervised hierarchical clustering with a published data set [28]. Cell lines are labeled by breast cancer
subtype; luminal-like (blue); basal-like (red); mesenchymal-like (green); unknown subtype (black). Displayed is an expanded view of selected gene
cluster containing basal-specific gene expression. The full gene cluster is provided as Figure S1.
doi:10.1371/journal.pone.0045684.g003
Table 2. Summary of DKAT marker expression (MEGM/
SCGM).
DKAT line
Marker MEGM media SCGM media
ER (2) (2)
PR (2) (2)
HER2 Not amplified Not amplified
EGFR (+) (+)
CK5 (++) (2)
CK14 (2) (2)
CK17 (++) (+/2)
CK8 (++) (+/2)
CK18 (++) (+/2)
E-cadherin
membrane (+) (2)
cytoplasmic (+) (+)
vimentin (+/2) (+++)
p63 (+) (2)
snail-1 (++) (++)
snail-2/slug (+) (+)
claudin-1 (+) (2)
claudin-4 (+) (2)
occludin (+) (2)
Akt (+) (+)
pAkt-Ser473 (+++) (++)
PTEN (2) (+)
p53 mutant mutant
PI3K wt wt
Qualitative evaluation based on immunofluorescence or western blot of DKAT
cells grown in MEGM or following 14 days in SCGM media.
doi:10.1371/journal.pone.0045684.t002
EMT/MET in Triple-Negative Breast Cancer
PLOS ONE | www.plosone.org 7 September 2012 | Volume 7 | Issue 9 | e45684
Figure 4. Evidence for morphologic and phenotypic changes consistent with in vitro EMT. A. Phase contrast or immunofluorescence
images of DKAT cells cultured in either MEGM (upper) or SCGM for 14 days (lower). Phase contrast images were acquired with a 206objective, scale
bar = 40 mm. IF images were acquired with a 406objective, scale bar = 20 mm. Cells were stained simultaneously for vimentin (green) and E-cadherin
EMT/MET in Triple-Negative Breast Cancer
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basement membrane. Pattern III: Intraductal and Pagetoid spread
(Figure 6Aiii). One xenograft was not palpable but was visible
when the host fat pad was exposed. This transplant lay flat in the
fat pad spreading along the ductal tree, but not forming a three-
dimensional mass. The whole mount revealed an abnormal
irregular branching pattern that is frequently found in outgrowths
(red), or CK18 (green) and CK5 (red). B. E-cadherin immunofluorescence images of DKAT cells cultured in MEGM or SCGM for 2 hours. C. Total cell
lysates from DKAT cells cultured in MEGM or SCGM for 1 h, 24 h, or 14 days were analyzed by western blot for vimentin, E-cadherin and actin. D.
Scratch wound healing assay comparing DKAT cells grown in MEGM or SCGM (14 days) and MDA-MB-231 cells. Images (upper panel) were taken at
the time of the scratch (T = 0) and 12 hours later with a 56objective. Scale bar = 200 mm. Results (lower panel) are expressed as the percentage of
the scratch area closed at 12 hrs as measured by ImageJ software, and are an average of 12 scratches per sample. E. Total cell lysates from a clonal
DKAT cell line cultured in MEGM or SCGM (14 days) were analyzed by western blot for vimentin, E-cadherin and actin. F. Total cell lysate from passage
matched cultures of DKAT cells grown in MEGM, SCGM, or SCGM for 10 passages and then returned to MEGM for 5 passages were analyzed by
western blot for epithelial and mesenchymal markers. G. Immunofluorescence (IF) images of subcloned DKAT-SCGM cells cultured in SCGM or MEGM
for 14 days. Cells were stained simultaneously for vimentin (green) and E-cadherin (red), and images were acquired with a 406objective. H. Total cell
lysates from the indicated cell lines cultured in their normal media or switched to MEGM or SCGM for 14 days were analyzed by western blot for
vimentin, E-cadherin, and actin expression. N=Normal, M=MEGM, S = SCGM.
doi:10.1371/journal.pone.0045684.g004
Table 3. Differential gene expression (MEGM/SCGM).
Fold Change
(MEGM to SCGM) Probe Set Gene Symbol Description
2131.8 213680_at KRT6C keratin 6C
237.0 201820_at KRT5 keratin 5
226.2 209863_s_at TP63 tumor protein p63
28.8 214580_x_at KRT6A keratin 6A
29.1 211194_s_at TP63 tumor protein p63
27.8 205157_s_at KRT17 keratin 17
26.7 204105_s_at NRCAM neuronal cell adhesion molecule
24.4 208083_s_at ITGB6 integrin, beta 6
24.0 200953_s_at CCND2 Cyclin D2
23.0 209351_at KRT14 keratin 14
22.9 222549_at CLDN1 claudin 1
23.0 229041_s_at ITGB2 integrin, beta 2
23.0 204990_s_at ITGB4 integrin, beta 4
23.0 217312_s_at COL7A1 collagen, type VII, alpha 1
22.5 209270_at LAMB3 laminin, beta 3
23.0 211473_s_at COL4A6 collagen, type IV, alpha 6
22.4 215177_s_at ITGA6 integrin, alpha 6
2.3 205016_at TGFA transforming growth factor, alpha
2.6 201506_at TGFBI transforming growth factor, beta-
induced
2.7 205422_s_at ITGBL1 integrin, beta-like 1
2.8 212489_at COL5A1 collagen, type V, alpha 1
2.9 215446_s_at LOX lysyl oxidase
3.4 204726_at CDH13 cadherin 13, H-cadherin
3.5 205885_s_at ITGA4 integrin, alpha 4
3.6 203180_at ALDH1A3 aldehyde dehydrogenase 1 family,
member A3
3.9 226622_at MUC20 mucin 20, cell surface associated
4.2 202016_at MEST mesoderm specific transcript homolog
5.6 203440_at CDH2 cadherin 2, type 1, N-cadherin
5.7 224480_s_at MAG1 lung cancer metastasis-associated
protein
6.0 204422_s_at FGF2 fibroblast growth factor 2 (basic)
List of genes related to the epithelial phenotype, cell-cell junctions, and motility with altered expression following 14 days of culture in SCGM to induce EMT. Microarray
experiments were performed as described in Materials and Methods.
doi:10.1371/journal.pone.0045684.t003
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of mouse mammary intraepithelial neoplasia. In some areas, the
tumor cells infiltrated as small nests between the myoepithelium
and the luminal cells of the mouse (Pagetoid spread). In other
areas, the human cancer cells were clearly invading the stroma
without any recognizable association with mouse mammary cells.
A dense inflammatory infiltrate surrounded all areas of the
outgrowth. DKAT cells stained for CK5, but did not stain for
vimentin.
The addition of Matrigel significantly affected the morpholog-
ical and staining patterns of DKAT xenograft tumors. DKAT
xenografts transplanted with Matrigel formed nests and cords of
cells that stained for both CK5 and SMA (Figure 6B), suggesting
the formation of myoepithelial cells. The peripheral cells infiltrated
surrounding tissue and enclosed nests of epithelial cells that stained
positive for CK8/18 and negative for SMA. The DKAT cells in
the center of the tumor (Figure 6B, left column) have larger nuclei
with open chromatin and more abundant cytoplasm. IHC for
SMA and CK5 shows clusters of unstained cells surrounded by
dual staining cells. In contrast, the invasive cells at the edge of the
tumor (Figure 6B, right column) from cords of cells that are
intensely positive for CK5 and some SMA.
Three-color immunofluorescence staining (human-specific p53,
CK14, and nuclear counter stain) was performed on the DKAT
xenograft tumors to confirm that the observed expression of
myoepithelial markers was due to heterogeneity of the DKAT
tumor cells, rather than infiltration of host cells in the tumor
microenvironment. The tumors contained human p53-positive
cells with varying levels of CK14 expression, demonstrating that
both the CK14-positive basal/myoepithelial cells and the more
luminal CK14-weak/negative cells are human DKAT tumor cells
(Figure 7A and 7B). There are also DAPI-positive cells that do not
stain for human p53, likely representing admixed mouse cells.
However, these cells are CK14 negative, confirming that the basal
and myoepithelial differentiation in the tumor originates from the
implanted DKAT tumor cells and not mouse fibroblasts or other
host cells. Taken together, these results show that DKAT cells in
vivo are invasive and exhibit phenotypic plasticity.
Single DKAT Cells can Generate Tumorspheres
Containing Both Epithelial and Mesenchymal Populations
We show that DKAT cells exhibit in vitro and in vivo plasticity.
Because a number of recent studies have demonstrated a link
between the EMT process and cancer stem cell properties, we
tested whether a single DKAT cell was capable of forming multi-
lineage cell clusters in non-adherent mammosphere culture
conditions. DKAT cells readily formed solid mammospheres
(tumorspheres) with a tumorsphere formation efficiency between 3
and 10%. Tumorspheres stained strongly for E-cadherin, b-
catenin, CK5, CK17, and CK18 (Figure 8), stained weakly for
SMA, and were negative for CK14 by immunofluorescence.
Interestingly, the DKAT tumorspheres contained dual populations
of cells that were either E-cadherin(+)/vimentin(2) or E-
cadherin(2)/vimentin(+). Dual staining for CK5 and CK18
demonstrated that tumorspheres also contained populations of
CK18(+)/CK5(low) and CK18(low)/CK5(+) cells (Figure 8). The
presence of tumorspheres with dual epithelial and mesenchymal
marker staining demonstrates that a single DKAT cell is able to
generate both epithelial and mesenchymal populations in tumor-
sphere culture conditions.
Discussion
Here we report the isolation of the DKAT cell line from a
highly aggressive triple-negative human breast cancer that
displayed morphological and biochemical characteristics sugges-
tive of EMT and MET. The human breast cancer from which the
DKAT cell line was isolated was comprised of multiple distinct
foci, the majority of which displayed an epithelial staining pattern.
However, one focus of the primary tumor, as well as the area of
invasion into the chest wall, displayed a more mesenchymal
phenotype, staining strongly for vimentin and diffuse, cytoplasmic
E-cadherin (Figure 1). Interestingly, metastatic tumor cells in the
bone marrow were found to have a staining pattern consistent with
a reversion to an epithelial phenotype (Figure 1).
Based on morphology and immunostaining, it was not possible
to determine whether this range of phenotypes was due to an
outgrowth of cell populations with a fixed phenotype, or rather
due to inherent phenotypic plasticity of the tumor cells. To explore
these possible explanations, we tested DKAT cells for phenotypic
plasticity in vitro using 2D and tumorsphere culture, and in vivo
using mouse xenografts. DKAT cells in culture demonstrated
evidence of phenotypic plasticity by reversible induction of
vimentin and decreased E-cadherin in response to serum-
containing media (Figure 4), and the formation of tumorspheres
containing both epithelial and mesenchymal markers in 3D
culture (Figure 8). Of the three most commonly-studied EMT-
inducing transcription factors Snail1, Zeb1, and Twist, we found
that only Zeb1 protein levels were increased during DKAT EMT,
and this induction was necessary for the increased migratory
ability of DKAT cells grown in SCGM (Figure 5).
An alternative explanation for the observed changes in DKAT
cell morphology and EMT marker expression is that culture in
SCGM selects for the outgrowth of a small pre-existing
Figure 5. Zeb1 regulates DKAT EMT/MET. A. Total cell lysate was
prepared from DKAT-MEGM or DKAT-SCGM cells and subjected to
western blot analysis for markers of EMT. B. Total cell lysate was
prepared from DKAT-MEGM cells stably transfected with a control
vector (V) or vector containing Zeb1 transcript (Zeb1) and subjected to
western blot analysis for markers of EMT. C. Scratch wound healing
assay comparing DKAT cells grown in MEGM or SCGM as indicated,
stably expressing either a non-targeting shRNA sequence or one of two
Zeb1-targeting sequences. Results are expressed as the percentage of
the scratch area closed at 16 hrs as measured by ImageJ software, and
are an average of 12 scratches per sample.
doi:10.1371/journal.pone.0045684.g005
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subpopulation of mesenchymal-like cells. In order to test for this
possibility we generated clonal cell lines from single DKAT cells in
MEGM. We found that these clonal lines generated from a single
cell were able to undergo in vitro EMT with the same kinetics as the
total DKAT population, providing evidence that this process is the
result of plasticity inherent to the cells, rather than a long-term
selection of a subpopulation of pre-existing mesenchymal cells
(Figure 4D).
Furthermore, when a clonal SCGM-DKAT cell line derived
from a single cell was cultured in MEGM, clusters of cells with
membranous E-cadherin and low expression of vimentin were
observed (Figure 4G). While not every cell underwent MET, these
clonal cell line experiments demonstrate that a single DKAT cell is
able to give rise to a population of cells capable of undergoing
EMT and MET. Indeed it is likely that not all the cells in the
DKAT population have the same potential for plasticity. The
DKAT cell line is likely heterogeneous, just as primary tumor
samples display heterogeneity among cells in their clonogenicity
and stem cell characteristics.
A number of recent studies have demonstrated a link between
EMT and the induction of stem cell-like characteristics in
mammary epithelial cells [10,27]. The DKAT cell line, which
was isolated from a triple-negative tumor, contains a high
percentage of CD44hi/CD242/(low) breast cancer stem-like cells
(Figure 3C). Tumorsphere culture of single DKAT cells resulted in
the growth of multi-lineage cell clusters with distinct populations of
epithelial (both luminal and basal) and mesenchymal cells
(Figure 8), further suggesting the inherent phenotypic plasticity
of DKAT cells and supporting the idea that a stem-cell phenotype
may be important in the epithelial plasticity of the cell line.
In our in vivo studies, similar to the multi-focal primary tumor
from which the cell line was derived, we found that DKAT
xenograft tumors exhibit a variety of phenotypes that appear to be
dependent on the microenvironment and illustrate the plasticity of
the DKAT cells (Figure 6). When placed into a standard
subcutaneous environment, they invade into the surrounding
tissue as cords of cells. When injected into an intact mammary fat
pad, they are able to invade and colonize the host ducts. In
Matrigel plugs, DKAT cells form nodules and nests with markers
of both luminal and myoepithelial differentiation. Though
traditional models of EMT involvement in tumor metastasis
suggest that EMT would occur at the tumor periphery, we see
SMA-positive DKAT cells in the center of the tumor. This is likely
due to the presence of growth factors in the Matrigel used in the
initial tumor cell injections. The in vivo plasticity of the DKAT cells
suggests that the EMT/MET observed in vitro is not merely an
artifact of the cell line adapting to culture conditions or selection of
a subclone. Taken together, our data provide strong evidence that
DKAT cells exhibit epithelial-mesenchymal plasticity, and that a
single DKAT cell is capable of giving rise to cells with
characteristics of multiple lineages.
Currently we are unable to reliably identify the subset of triple-
negative breast cancers that are clinically aggressive and have the
worst prognosis. Several new subtypes have been proposed within
the triple-negative group based on gene expression patterns,
including the Basal B, metaplastic, and claudin-low subtypes
[18,31,35]. These marker classification systems are an important
step forward in understanding the biology of aggressive breast
tumors; however, the phenotypic plasticity of DKAT cells makes it
difficult to precisely classify these cells by fixed marker expression
studies and gene expression profiles. For example, DKAT cells
induced to undergo in vitro EMT show reduced expression of tight
junction proteins associated with the claudin-low phenotype; such
classification may therefore be significantly influenced by culture
conditions in vitro and the microenvironment in vivo.
While there has been intense interest in the study of EMT as it
relates to breast cancer, there is still controversy over its
contribution to cancer progression in patients. Without live image
tracking or genetic tracing, the human tumor data presented here
can only provide evidence of clonal heterogeneity. However, our in
vitro experiments and in vivo xenograft studies demonstrate that a
cell line derived from this cancer displays evidence suggestive of
reversible EMT/MET and phenotypic plasticity. In both the total
DKAT population and the clonal cell lines we observe that
following the transition to SCGM, the acquisition of mesenchymal
morphology and upregulation of vimentin are rapid events,
evident within one hour. While E-cadherin is rapidly localized
away from the membrane into the cytosol within 2 hours
(Figure 4B) we do not observe decreased levels of total E-cadherin
protein until after day 14. These observations are consistent with
other reports that Zeb1 can inhibit expression of epithelial genes
through recruitment of HDACs to target promoters, resulting in a
repressive chromatin environment [36,37]. This method of E-
cadherin repression may partially explain the delayed reduction in
E-cadherin protein levels, as well as the observed delay in re-
expression of E-cadherin during the process of MET [36,37].
Importantly, our results from the DKAT model of plasticity are
consistent with clinical observations, namely that a full EMT is
rarely seen in human cancer; rather, a partial EMT phenotype is
most commonly observed in which cells exhibit both epithelial and
mesenchymal traits simultaneously. The relevance of our studies to
human cancer is underscored by recent data showing circulating
tumor cells (CTCs) that stain positively for cytokeratin, vimentin,
and N-cadherin were found in the majority of men with castration-
resistant metastatic prostate cancer and women with metastatic
breast cancer [38]. This intermediate epithelial-mesenchymal
staining pattern of the CTCs suggests that epithelial plasticity,
even within a small percentage of the tumor cell population, may
be a driving factor in metastasis.
Traditional models of invasion and metastasis hypothesize that
metastatic breast cancer results from the outgrowth of a
subpopulation of cells with defined morphology and gene
expression patterns, and that these cells are unique in their ability
to migrate away from the primary tumor and establish a distant
metastasis [39]. It has also been suggested that the aggressive
metastatic behavior of certain subtypes of breast cancer (i.e. triple-
negative) may reflect properties of the cell of origin from which the
cancer arose [40], and more recently that the process of EMT
itself may endow cancer cells with stem cell-like properties,
enhancing their metastatic potential [10,27,41]. The ability of the
DKAT cells to undergo reversible EMT in response to changes in
culture conditions and their ability to form xenograft tumors with
regions of both epithelial and mesenchymal characteristics
provides evidence that the aggressive behavior of a subset of
triple-negative breast cancers may be driven by the inherent
phenotypic plasticity of the primary tumor. The DKAT model
Figure 6. Comparison of H&E and IHC patterns from DKAT xenografts. A. IHC showing H&E (i and ii) or CK5 staining (iii) illustrating the three
recurring morphological patterns observed in DKAT xenografts transplanted without Matrigel. B. IHC showing H&E, CK8/18, CK5, and SMA staining of
DKAT xenografts transplanted with Matrigel. The left column shows the center of a transplant and the right column shows the leading edge of the
tumor.
doi:10.1371/journal.pone.0045684.g006
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represents a unique triple-negative tumorigenic epithelial cell line
that can undergo both EMT and MET in culture and is well suited
for studies of the molecular mechanisms that regulate phenotypic
plasticity in triple-negative breast cancer.
Materials and Methods
Establishment of the DKAT Cell Line
Pleural fluid from a patient with biopsy-confirmed primary
breast cancer was obtained with the approval of The Ohio State
University Institutional Review Board and with the written
informed consent of the patient. Pleural fluid was centrifuged to
pellet the cells. The pellet was then resuspended in Mammary
Epithelial Cell Growth Medium (MEGM) supplemented with
bovine pituitary extract, insulin, human recombinant epidermal
growth factor, and hydrocortisone (Lonza, Basel, Switzerland).
Mycoplasma testing was as previously reported [42].
Other Cell Lines
Primary human mammary epithelial cells (HMECs) (Lonza)
were immortalized with hTERT (HMEC-hTERT), and main-
tained in supplemented MEGM. MDA-MB-231 and MCF-7 cells
(American Type Culture Collection [ATCC], Manassas, VA) were
maintained in aMEM (Invitrogen, Carlsbad, CA) supplemented as
previously described [43]. SUM-190 cells (ATCC) were main-
tained in RPMI supplemented with 10% FBS.
Cytogenetic Analysis
Spectral karyotyping analysis (SKY) was performed as previ-
ously described [44]. Karyotypic abnormalities were classified
according to the International System for Human Cytogenetic
Nomenclature.
Immunohistochemisty
The human formalin-fixed, paraffin-embedded primary breast
biopsy, chest wall recurrence, and bone metastasis samples were
sectioned at 4 mm thickness and stained for alpha-smooth muscle
actin (1A4, Sigma), vimentin (3B4 Boehringer Mannheim Roche,
Hvidovre, Denmark), CK5 (OVTM, DAKO, Glostrup, Denmark)
and wide range keratins (MNF116, DAKO). The antibodies were
visualized by streptavidin-biotin (DAKO 5004).
TP53 and PIK3CA Sequencing
Sequencing of exons 5–9 of the TP53 gene and exons 9 and 20
of PIK3CA using previously published primers and programs
[IARC TP53 Mutation Database, http://www-p53.iarc.fr/
p53sequencing.html and [45]] was performed on genomic DNA
isolated from passage 20 DKAT cells. Mutations were tested in
both the sense and antisense sequences and were confirmed by
repeat sequencing of a second, independent genomic DNA
preparation.
Immunofluorescence
Cells were fixed in either methanol for 20 minutes or 4%
paraformaldehyde for 30 minutes on ice. Cells were blocked for 30
minutes, incubated with primary antibody overnight at 4uC and
secondary antibody for 1 hour at RT, and counter stained with
DAPI. Images were acquired on a Zeiss Axio Observer A1
fluorescence microscope (Carl Zeiss, Go¨ttingen, Germany) with a
40 6 or 63 6 objective. Primary antibodies were from 1) Santa
Cruz Biotechnology Inc. (Santa Cruz, CA): CK5 (sc-66856),
CK14 (sc-53253), CK18 (sc-28264), CK17 (sc-101931), E-
cadherin (sc-7870), EGFR (sc-120), ERalpha (sc-8005), p63 (sc-
56188), and vimentin (sc-5565) 2) BD biosciences (San Jose, CA):
vimentin (550513), E-cadherin (610181) 3) Thermo Fisher
Scientific Inc. (Fremont, CA): PR (MS-298) 4) Abcam (Cam-
bridge, MA): smooth muscle actin (ab15734), and 5) Invitrogen
(Carlsbad, CA): claudin-1 (37–4900), claudin-4 (32–9400), ZO-1
(40–2300), occludin (40–4700), goat anti-mouse Alexa-fluor 488
(A21222) and goat anti-rabbit Alexa-fluor 597 (A11070) secondary
antibodies.
Western Blotting
Antibodies were p53 (DO-1, Santa Cruz Biotechnology Inc.,
Santa Cruz, CA); PTEN, Akt-pSer473, Akt-1, Akt-2, Akt-3 (9552,
4051 and 4058, 2967, 2964, 3788, respectively, Cell Signaling,
Danvers, MA); claudin-1, claudin-4, occludin, ZO-1 (37–4900,
32–9400, 40–4700, and 40–2300, respectively; Invitrogen, Carls-
bad, CA), snail-1 (gift from Antonio Garcia-deHerreros). Loading
control was provided by reprobing the membrane with an
antibody to beta-actin (I19, Santa Cruz Biotechnology, Inc.).
Images were captured using the Kodak Image Station 2000 MM
and quantified using Kodak 1D Image Analysis Software (East-
man Kodak, Rochester, MN).
FACS Analysis
Cells were harvested with cell dissociation buffer (Invitrogen)
and incubated with APC-conjugated CD44 and PE-conjugated
CD24 antibodies (BD Biosciences, San Jose, CA). Fifty thousand
events were collected using a FACSCaliber flow cytometer and
analyzed for CD44/CD24 expression with CellQuest software
(BD Immunocytometry Systems).
Differential Gene Expression Studies
mRNA was collected using the Qiagen RNeasy mini kit with
the optional DNAse step (Quiagen, Valencia, CA) and RNA
integrity was confirmed by electrophoresis. cRNA synthesis and
probe generation for cRNA array hybridization were performed
according to the standardized protocols provided by Affyme-
trixTM (Affymetrix, Santa Clara, CA). Transcript analysis was
performed using Affymetrix HG-U133 Plus2.0 GeneChips.
Samples were labeled and hybridized following strict adherence
to Affymetrix’s standardized protocols. GeneChip results were
assessed for quality prior to further analysis. Median expression
values of technical replicates (n = 3) for each of three cell lines,
HMECs, DKAT, and MDA-MB-231, were compared with
published breast cancer cell line expression data downloaded
from the publisher’s web site [28]. Probe Set IDs were used to
merge the two data sets (16,383 features). Duplicate Gene
Symbols were summarized by mean Probe Set ID values. The
data were array- and gene-wise median centered and filtered to
exclude genes with standard deviations of observed values less
Figure 7. Basal/myoepithelial differentiation of DKAT xenografts. A. DKAT xenograft tumor stained with DAPI (blue) nuclear counter stain,
CK14 (green) showing basal/myoepithelial differentiation of tumor cells, and human-specific p53 (red) confirming that both the CK14-positive cells
and the more luminal, CK14 weak/negative cells are human DKAT tumor cells. 100 micron scale bar in the DAPI channel applies to all four images. B.
DKAT tumor from a second mouse at higher magnification shows an area of vague glandular architecture with somewhat elongated CK14-positive
basal/myoepithelial cells (arrows) surrounding CK14 weak/negative cells which surround a poorly formed glandular lumen (asterix). 25 micron scale
bar show in in DAPI channel.
doi:10.1371/journal.pone.0045684.g007
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Figure 8. DKAT tumorsphere culture. Immunofluorescence of DKAT tumorspheres stained for E-cadherin, b-catenin, CK17 and CK18 (upper and
middle panels). Tumorspheres were also dual stained for E-cadherin (red) and vimentin (green), or CK5 (red) and CK18 (green) (lower panel). Images
were acquired with a 636objective. Scale bar = 40 mm.
doi:10.1371/journal.pone.0045684.g008
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than 1.5. The remaining 473 features were clustered using
centroid linkage and Pearson correlation as the similarity metric
(Cluster ver. 3.0). Data has been submitted to the NCBI GEO
in accordance with MIAME guidelines.
Migration Assays
56105 DKAT or MDA-MB-231 cells were plated in 6-well
plates and cultured until confluent. The cell monolayer was then
scratched with a pipette tip, rinsed, and photographed at regular
intervals until the scratch was completely closed. The area of the
scratch was measured using ImageJ software [46], and results are
expressed as a percentage of the original scratch area filled by the
cells at the indicated timepoint.
In vitro Plasticity
EMT: DKAT cells were switched from MEGM to SCGM
(Lonza); DKAT control cells remained in MEGM. Time in
SCGM ranged up to 10 passages, and control DKAT cells were
maintained in MEGM and passaged in parallel. MET: After 10
passages in SCGM, a portion of DKAT cells were switched back
to MEGM. Control cells included 1) the original DKAT cells
grown continuously in MEGM and 2) DKAT cells maintained in
SCGM. All cells and controls were passaged in parallel and
imaged and harvested at similar confluency.
Clonal Cell Line Generation
DKAT cells in MEGM were digested into a single-cell
suspension with trypsin and plated at one cell per well in a 96
well plate, and wells were visually checked for the formation of
colonies. After 22 days, cells were removed from wells containing
colonies by cell dissociation buffer (Invitrogen) and sequentially
grown out in a 24-well plate, 6-well plate, T25 flask, and T75 flask.
In vitro EMT was induced as previously described.
Zeb1 Expression
The full-length Zeb1 transcript was amplified from MDA-MB-
231 cells by PCR using the following primers: Forward 59-CAA
GCG AGA GGA TCA TGG CG-39 and Reverse 59-TTC CTT
CTA GAA AAA CGA TTA GGC-39. The resulting product was
cloned into the XhoI and BamHI sites of pLXSN. Retroviral
particles were generated by transfecting the resulting construct or
the pLXSN empty vector control into GP293 cells. DKAT-
MEGM cells were then transduced and expressing cells were
selected with 0.5 mg/ml G418 (Invitrogen).
Zeb1 shRNA
Mission shRNA constructs targeting Zeb1 and a non-targeting
control construct were purchased from Sigma, and lentivirus was
produced according to manufacturer’s instructions. DKAT cells in
MEGM were transduced and selected with 0.5mg/ml Puromycin,
and the resulting cells were grown in either MEGM (control) or
SCGM to induce EMT. Scratch assays were performed at least 14
days after the transition to SCGM.
Xenograft Experiments
DKATcells grown inMEGMwere tested for xenograft growth by
limitingdilution;104,103,102,or10cellswereresuspended in50 mlof
either 1) 1:1/v:v PBS:MatrigelTM or 2) PBS alone, and injected into
the right and left uncleared #4 mammary fat pad of NOD.CB17-
PrkdcSCID/Jmice. Four independent experiments (eight replicates
perexperiment)wereperformedatDukeUniversityandUniversityof
California at Davis (UCD). DKAT xenografts using matrigel were
performedwithNODCB17-Prkdc SCID/Jmice (JacksonLabs) and
were performed in accordancewith aprotocol approvedby theDuke
University Institutional Animal Care and Use Committee (protocol
number A328-08-12). Tumor growth was assessed weekly by
measuring tumor volume by caliper. Mice were sacrificed when the
tumor reached 1.5 cm in diameter or after 150 days. Tumors were
excised, fixed in 4% paraformaldehyde at 4uC overnight, sectioned
and stained, and underwent central pathology review at UCD.
DKAT xenografts without matrigel were performed in nude and
NODCB17-PrkdcSCID/Jmice (JacksonLabs) inaccordancewitha
protocol approved by the UCD Institutional Animal Care and Use
Committee (protocol number 13217). All efforts were made to
minimize suffering.
Xenograft Immunofluorescence Staining
Three color (p53, keratin 14, nuclear counterstain) immunoflu-
orescence staining was performed using standard protocols.
Briefly, fresh frozen paraffin embedded 4 micron sections were
mounted on positively charged slides, deparaffinized with xylene
and washed in absolute ethanol. Endogenous peroxidase was
quenched, and tissue was rehydrated prior to antigen retrieval
(citrate, pH=6.0, 2 minutes at 95uC). Tissue was blocked with
Serum-Free Block (DAKO X090) for 15 minutes, then incubated
at 4uC overnight with primary antibodies, 1:500 anti-p53 goat
polyclonal (Santa Cruz FL-393-G), 1:200 anti-keratin 14 rabbit
polyclonal (Thermo Scientific RB-9020-P1) in PBS with ovalbu-
min. After washing 5 minutes twice in PBS at room temperature,
the tissue was first incubated in 1:500 donkey anti-rabbit
conjugated with Alexa Flour 488 (Invitrogen A21206) in PBS at
room temperature for 30 minutes. After washing again 5 minutes
twice in PBS, the tissue was incubated in 1:500 rabbit anti-goat
conjugated to Rhodamine (Millipore AP106R) in PBS at room
temperature for 30 minutes, then washed twice in PBS for 5
minutes and coverslipped using DAPI Vectashield (Vector Labs),
sealed with clear nail-polish and imaged. Images were acquired on
a Zeiss Axiophot fluorescent microscope equipped with band-pass
filters for FITC, DAPI, and Rhodamine. Images were obtained
using a cooled CCD Zeiss color AxioCam and software. Image
overlays were produced in Photoshop (Adobe).
Tumorsphere Assays
Tumorsphere culture was performed as previously described [47]
with minor modifications. Briefly, cells were plated at 1 cell/well in
96-well ultra-low attachment plates in MEGM containing B27,
Heparin,EGF,andbFGF.Cellswerecultured for10–14daysandthe
tumorsphere formation efficiency was determined by counting the
number of tumorspheres anddividing by the number ofwells seeded.
For immunofluorescence studies, DKAT cells were plated at 103
cells/100 mm dish. Ten-14 days later, tumorspheres were pooled
and fixed in 100% ice coldmethanol, and staining was performed as
described above. Tumorsphere images were acquired with an SP5
Leica laser scanning confocal microscope.
Supporting Information
Figure S1 Differential gene expression studies. Median
expression values of technical replicates (n = 3) for each of three
cell lines, HMECs, DKAT, and MDA-MB-231 (orange) were
analyzed by unsupervised hierarchical clustering with a published
data set [28]. The results were displayed using Java TreeView (ver.
1.1.0). Cell lines are labeled by breast cancer subtype: luminal-like
(blue), basal-like (red), mesenchymal-like (green), or unknown
subtype (black).
(PDF)
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